Special Feature "Medical DX
Digital and Data Pioneering the Frontiers of DX in Japanese Healthcare
Medical DX is the key to delivering optimal, high-quality medical care in Japan, where the population is declining and aging. We introduce "co-creation" efforts that transcend industry boundaries, including interviews with former Digital Agency experts, promotion of data linkage by the Pharmaceutical Manufacturers Association of Japan (PMAJ) Task Force, and the latest trends in AI drug discovery.
From JPMA
Interview with former Executive Vice President Mori - Creating Value Together: Co-creation to Pioneer Truly Patient-Centered Medicine
Former Executive Director Mori, who retired in September of this year, will talk about the philosophy of "Co-creation" beyond the traditional "Patient Centricity" and how it has been put into practice in the Pharmaceutical Manufacturers Association of Japan (PMAJ). He will talk about the improvement of information access and the "Co-creation Meeting" to revitalize the organization, as well as how to pass it on to the next generation.
My Committee
vol.4 Environmental Issues Study Group
The pharmaceutical industry accounts for about 90% of GHG emissions, and the industry is working to decarbonize its Scope 3 (the entire supply chain). Following the adoption of the Ministry of the Environment's model project, we will introduce the activities of the Environmental Issues Study Group, which is working on "co-creation" to formulate guidelines for industry-wide Scope 3 calculation and primary data generation.
The Pharmaceutical Industry from a Factual Perspective
Survey on EBP-derived drugs in the U.S.
The success factors of EBPs in the U.S., which are increasing their presence as drug discovery modalities diversify, will be examined in depth from the four facts of "funding strategy," "diverse human resources," "collaborative structure," and "business orientation," and specific suggestions for revitalizing the drug discovery ecosystem in Japan will be explored.
Topics
Introduction of various topics within the association
We will present the latest developments, including the students' perception of the pharmaceutical industry as a "challenging industry," the Pharmaceutical Manufacturers Association's first "Co-creation Meeting" to realize Vision 2035, and the release of TPP, a common language for drug research and development that encourages collaboration among academia.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire